Business
Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares
About this update from Glucotrack, Inc.
[{"type":"image","alt":"GlucoTrack, Inc.","displaySize":"","headline":null,"caption":"GlucoTrack, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/34ddda24ce1daf5f60ba6f7c2be22d4a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jLjmYeICxeIiiA5nYSpJ3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/34ddda24ce1daf5f60ba6f7c2be22d4a","width":300,"height":64}},"lazy":false},{"type":"text","content":"Rutherford, NJ., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 1,033,591 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,067,182 shares of common stock at an effective combined price of $3.87 per share and common warrant for aggregate gross proceeds of approximately $4.0 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $3.87 per share, will not be exercisable until receipt of shareholder approval and will expire five years from the initial exercise date.","length":894,"tagName":"p"},{"type":"text","content":"The closing of the offering is expected to occur on or about December 31, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.","length":254,"tagName":"p"},{"type":"text","content":"Curvature Securities LLC is acting as the sole placement agent in connection with the offering.","length":95,"tagName":"p"},{"type":"text","content":"The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws. Ac...